All In Biotech

Drug Trial Radar · NCT01208090

ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis

Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety & Tolerability of Two Doses of ACT-128800, an Oral S1P1 Receptor Agonist, Administered up to Twenty-eight Weeks in Patients With Moderate to Severe Chronic Plaque Psoriasis

Last checked: Nov 20, 2026Latest source record: Mar 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 326 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

326

Actual

Start

Oct 31, 2010

Primary completion

Oct 31, 2012

Study completion Nov 30, 2012

Sponsor

Lead sponsor
ActelionJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Sep 23, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the efficacy, safety and tolerability of two doses of ACT 128800 in patients with moderate-to-severe chronic plaque psoriasis.

Conditions

  • Psoriasis

Interventions

  • ACT-128800Drug

    ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily

  • PlaceboDrug

    ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients with at least 75% improvement in PASI from baseline (PASI75) at Week 16.Time frame: Baseline to week 16

Locations

67 sites in 17 countries. Site status is shown where the registry gives one.

  • Clinical Investigative Site 1006

    Feldkirch, Austria

  • Clinical Investigative Site 1002

    Graz, Austria

  • Clinical Investigative Site 1004

    Sankt Pölten, Austria

  • Clinical Investigative Site 1007

    Vienna, Austria

  • Clinical Investigative Site 1001

    Vienna, Austria

  • Clinical Investigative Site 1103

    Brussels, Belgium

  • Clinical Investigative Site 1102

    Edegem, Belgium

  • Clinical Investigative Site 1101

    Liège, Belgium

  • Clinical Investigative Site 1205

    Pleven, Bulgaria

  • Clinical Investigative Site 1204

    Plovdiv, Bulgaria

  • Clinical Investigative Site 1202

    Sofia, Bulgaria

  • Clinical Investigative Site 1201

    Sofia, Bulgaria

  • Clinical Investigative Site 1203

    Sofia, Bulgaria

  • Clinical Investigative Site 1206

    Stara Zagora, Bulgaria

  • Clinical Investigative Site 1402

    Hradec Králové, Czechia

  • Clinical Investigative Site 1405

    Nový Jičín, Czechia

  • Clinical Investigative Site 1406

    Pardubice, Czechia

  • Clinical Investigative Site 1401

    Prague, Czechia

  • Clinical Investigative Site 1502

    Copenhagen, Denmark

  • Clinical Investigative Site 1504

    Roskilde, Denmark

  • Clinical Investigative Site 1704

    Bordeaux, France

  • Clinical Investigative Site 1701

    Nice, France

  • Clinical Investigative Site 1707

    Paris, France

  • Clinical Investigative Site 1710

    Paris, France

  • Clinical Investigative Site 1705

    Pierre-Bénite, France

  • Clinical Investigative Site 1703

    Poitiers, France

  • Clinical Investigative Site 1702

    Saint-Etienne, France

  • Clinical Investigative Site 2002

    Budapest, Hungary

  • Clinical Investigative Site 2001

    Debrecen, Hungary

  • Clinical Investigative Site 2006

    Miskolc, Hungary

  • Clinical Investigative Site 2005

    Pécs, Hungary

  • Clinical Investigative Site 2003

    Szeged, Hungary

  • Clinical Investigative Site 2004

    Veszprém, Hungary

  • Clinical Investigative Site 2315

    Ancona, Italy

  • Clinical Investigative Site 2303

    Bergamo, Italy

  • Clinical Investigative Site 2307

    Bologna, Italy

  • Clinical Investigative Site 2317

    Genova, Italy

  • Clinical Investigative Site 2309

    L’Aquila, Italy

  • Clinical Investigative Site 2310

    Pisa, Italy

  • Clinical Investigative Site 2304

    Roma, Italy

Showing 40 of 67 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.